Paper Details

  1. Home
  2. Paper Details

Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.

Author: KakuSeiji, OhtakeAkiyoshi, TaharaAtsuo, TakamatsuHajime, Tanaka-AminoKeiko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This preclinical study investigated the effects of repeated fezolinetant administration in ovariectomized rats, a model of menopause. Fezolinetant, an NK3 receptor antagonist, dose-dependently reduced plasma LH levels, inhibited the activation of MnPO neurons, and attenuated hot flash-like symptoms, suggesting its potential for treating VMS associated with menopause.
Paper Details　
Original Abstract of the Article :
The majority of women experience vasomotor symptoms (VMS), such as hot flashes and night sweats, during the menopausal transition. Recent evidence strongly suggests a connection between neurokinin 3 (NK3) receptor signaling and VMS associated with menopause. The NK3 receptor antagonist fezolinetant ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejphar.2021.174207

データ提供：米国国立医学図書館（NLM）

Fezolinetant: A Potential Treatment for Menopausal Hot Flashes

This study explores the potential of fezolinetant, a neurokinin 3 (NK3) receptor antagonist, as a treatment for hot flashes, a common symptom associated with menopause. The researchers used ovariectomized rats, a model of menopause, to investigate the effects of fezolinetant on hot flash-like symptoms.

Fezolinetant Demonstrates Promise in Reducing Hot Flashes

The study found that repeated administration of fezolinetant significantly attenuated hot flash-like symptoms in ovariectomized rats. This suggests that fezolinetant may be a promising therapeutic option for managing hot flashes in menopausal women. The study also found that fezolinetant reduced hyperphagia (excessive eating) and weight gain in ovariectomized rats.

Fezolinetant: A Potential for Improved Menopause Management

These findings provide further support for the ongoing clinical development of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. This research offers hope for developing more effective treatments for women experiencing the discomfort and challenges of menopause.

Dr. Camel's Conclusion

Fezolinetant shows promise as a treatment for hot flashes associated with menopause. The researchers found that it significantly reduced hot flash-like symptoms in ovariectomized rats. This research suggests that fezolinetant may offer a new and effective option for women struggling with menopause symptoms.
Date :
  1. Date Completed 2021-10-01
  2. Date Revised 2021-10-01
Further Info :

Pubmed ID

34048742

DOI: Digital Object Identifier

10.1016/j.ejphar.2021.174207

Related Literature

Article Analysis
・Effects of fezolinetant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.